BNP Paribas Asset Management
RARE icon

BNP Paribas Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

BNP Paribas Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Sell
409,255
-8,894
-2% -$221K 0.01% 662
2026
Q1 		$8.76M Sell
418,149
-1,481,512
-78% -$33.4M 0.01% 719
2025
Q4 		$43.7M Buy
1,899,661
+354,382
+23% +$11.7M 0.05% 336
2025
Q3 		$46.5M Buy
1,545,279
+93,149
+6% +$2.79M 0.12% 183
2025
Q2 		$52.8M Buy
1,452,130
+301,674
+26% +$10.9M 0.13% 163
2025
Q1 		$41.7M Buy
1,150,456
+192,379
+20% +$8M 0.11% 196
2024
Q4 		$40.3M Buy
958,077
+233,895
+32% +$11.6M 0.1% 214
2024
Q3 		$40.2M Sell
724,182
-106,193
-13% -$5.41M 0.1% 209
2024
Q2 		$34.1M Buy
830,375
+323,280
+64% +$13.8M 0.09% 232
2024
Q1 		$23.7M Buy
507,095
+424,476
+514% +$20M 0.06% 281
2023
Q4 		$3.95M Buy
+82,619
New +$3.2M 0.01% 567
2022
Q3 		– Sell
-8,139
Closed -$486K – 959
2022
Q2 		$486K Buy
+8,139
New +$501K ﹤0.01% 849

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

BNP Paribas Asset Management's RARE Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 2.1% in Q2 2026, selling an estimated $221K and leaving 409,255 shares worth $13.7M. The position accounts for 0.01% of the portfolio, ranked #662.

BNP Paribas Asset Management first reported a position in RARE in Q2 2022 and has held it in 12 quarters since. The position peaked at $52.8M in Q2 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • BNP Paribas Asset Management held 409,255 shares of Ultragenyx Pharmaceutical worth $13.7M as of Q2 2026.
  • BNP Paribas Asset Management sold 8,894 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $221K.
  • Ultragenyx Pharmaceutical made up 0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #662 holding.
  • BNP Paribas Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2022 and has held it in 12 quarters since.
  • BNP Paribas Asset Management's Ultragenyx Pharmaceutical position peaked at $52.8M in Q2 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.